found Documents: 881

Announcements & Press Releases, Oncology / Immunology | 5 Sep 2018

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

1 item

– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate® – – Elunate® data published in JAMA demonstrated increased overall survival versus placebo – – F

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Aug 2018

Total Voting Rights

1 item

London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

Total Voting Rights

Grant of Share Options under Share Option Scheme

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

Total Voting Rights

Blocklisting Six Monthly Return

Chi-Med to Announce 2018 Half-Year Financial Results

Grant of Share Options under Share Option Scheme

Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

Total Voting Rights

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

Total Voting Rights

Results of AGM Meeting

Block Admission

Grant of Share Options under Share Option Scheme

Total Voting Rights

Vesting of awards under the Long Term Incentive Plan

2017 Annual Report and Notice of Annual General Meeting

Director’s Share Dealing

Grant of Share Options under Share Option Scheme

Director's Share Dealing

Publication of Form 20-F for the Year Ended December 31, 2017

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China

Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer

Chi-Med to Announce 2017 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

TR-1: Notification of major interest in shares

TR-1: Notification of major interest in shares

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

Chi-Med Announces Proposed Offering of ADSs (RNS)

Chi-Med Announces Proposed Offering of ADSs

TR-1: Notification of major interest in shares

Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

Chi-Med Appoints Professor Tony Mok to Board of Directors

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Total Voting Rights

Director's Share Dealing

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

Director's Share Dealing

Directors' Share Dealing